---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-118525"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2026-03-23T23:59:59+00:00"
generated_at: "2026-05-15T09:23:14.002540+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology completes MICVO enrollment, reports FY2025 net loss of $79.6M, names Interim CEO

## Summary
- Completed target enrollment (n~40) for MICVO Phase 1 monotherapy dose expansion in 2L+ R/M HNSCC in Q1 2026.
- Updated MICVO monotherapy data expected mid-2026; combination data with KEYTRUDA expected 2H26.
- Appointed Thomas Civik as Interim CEO; added SVPs of Global Clinical Ops, IR/Capital Markets, and Global Program Leader.
- Cash and investments $68.3M at Dec 31, 2025; expected cash runway into Q4 2026.
- FY2025 net loss $79.6M ($1.28/diluted) vs $77.3M ($1.32) in 2024; revenue $13.9M from royalty sale.

## SEC filing metadata
- accession: 0001193125-26-118525
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2026-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000119312526118525/0001193125-26-118525-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000119312526118525/pyxs-20260323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-118525
- JSON: https://secwatch.observer/filing/0001193125-26-118525.json
- Plain text: https://secwatch.observer/filing/0001193125-26-118525.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.